Zacks Research Analysts Boost Earnings Estimates for Hologic

Key Points

• Hologic's Q2 2026 earnings per share estimate has been raised from $1.05 to $1.06 by Zacks Research, while the full-year earnings consensus is $4.28 per share.
• The company's recent quarterly earnings report revealed a net margin of 13.79% and a return on equity of 19.69%, with revenue of $1.02 billion surpassing estimates.
• Recent analyst ratings show mixed opinions, with a shift from "buy" to "hold" by some, while others have set target prices ranging from $69.00 to $87.00 for Hologic shares.

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Investment analysts at Zacks Research raised their Q2 2026 earnings estimates for shares of Hologic in a report released on Wednesday, September 17th. Zacks Research analyst Team now anticipates that the medical equipment provider will earn $1.06 per share for the quarter, up from their prior forecast of $1.05. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic's FY2026 earnings at $4.39 EPS and FY2027 earnings at $4.78 EPS.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter in the previous year, the business posted $1.06 earnings per share. Hologic's quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS.

Several other research analysts have also commented on the stock. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and raised their price target for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. Mizuho set a $75.00 price target on Hologic in a research note on Thursday, July 31st. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Evercore ISI raised their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Finally, Stephens reiterated an "overweight" rating and issued a $78.00 price target on shares of Hologic in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Hologic presently has an average rating of "Moderate Buy" and a consensus target price of $79.38.

Hologic Trading Down 2.8%

NASDAQ HOLX traded down $1.94 during trading on Friday, hitting $66.33. The stock had a trading volume of 8,515,121 shares, compared to its average volume of 1,762,988. The firm has a 50 day moving average price of $66.47 and a 200 day moving average price of $62.75. The company has a market capitalization of $14.75 billion, a PE ratio of 27.52, a PEG ratio of 2.40 and a beta of 0.57. Hologic has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Institutional Investors Weigh In On Hologic

Large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its holdings in Hologic by 294.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider's stock worth $718,223,000 after acquiring an additional 8,227,318 shares during the last quarter. Invesco Ltd. lifted its holdings in Hologic by 72.5% in the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider's stock worth $543,486,000 after purchasing an additional 3,505,828 shares in the last quarter. Norges Bank bought a new position in shares of Hologic during the 2nd quarter valued at approximately $180,055,000. Victory Capital Management Inc. grew its position in shares of Hologic by 34.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after buying an additional 1,692,177 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Hologic by 473.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider's stock worth $111,180,000 after purchasing an additional 1,405,085 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.